CA2373239A1 — Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response

USPTO Abstract

The invention relates to a stability and biocompatibility-optimized adjuvant (SBA) for enhancing the humoral and cellular immune response by jointly injecting said adjuvant with one or more antigens. The adjuvant consists of particles based on solid lipids or solid lipid mixtures and can be used in the production of more efficient and compatible vaccines, the inoculation of human beings and animals and for obtaining antibodies. The strength of the immune response can be modulated in a targeted manner and additionally adapted to the specific species by selecting the size, charge and surface characteristics of the particles. Other adjuvants, e.g. molecular adjuvants such as GMDP, can be added to the SBA, whereby the cellular immune response is additionally enhanced. The SBA is more effective and cost-efficient and easier to use than existing products and is well tolerated in vivo.